Navigation Links
Outstanding transfection rates using the Multiporator

Using eukaryotic cells, extremely high transfection rates can be achieved due to a hypoosmolar buffer system and short pulses in the s-range. High reproducibility is ensured by an electronically controlled pulse, independent of sample resistance (patent pending). Experimental data
Two cell lines (mouse fibroblast cells, human T-lymphocytes) were transfected using plasmid-DNA and two different electroporation systems, the new Eppendorf Multiporator (A) and a system of a well-known competitor (B).

Transfections were performed according to the manufacturers protocols. Transfection rates were calculated using FACS analysis.

Transfection rates after 48 h in relation to initial number of cells
Multiporator (A) Competitor (B)
Mouse fibroblast cells 54.25%
22.16%
n=8
2.03%
1.12%
n=8
Human T-lymphocytes 29.92%
9.26%
n=10
0.55%
0.6%
n=10




'"/>

Source:


Page: All 1

Related biology technology :

1. Outstanding transfection rates using the Multiporator
2. Efficient DNA transfection of primary CNS neurons using TransMessenger Transfection Reagent
3. Monitoring transfection efficiency by green fluorescent protein (GFP) detection with the Agilent 2100 bioanalyzer
4. Confirming gene silencing mechanism by pGFP/GFP22 siRNA co-transfection
5. siRNA transfection optimization with the Agilent 2100 bioanalyzer
6. New Kit Generates Exceptionally Pure Total RNA for RT-PCR
7. High-Throughput System Generates Ultra-Pure PCR Products Suitable for All Applications
8. A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20)
9. Isolation of Cosmids using Eppendorfs Perfectprep Plasmid Mini Kit
10. Normalizing cDNA libraries using the EppendorfThermomixer
11. Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):